These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1164 related items for PubMed ID: 34994987

  • 1. Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.
    Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V.
    Cochrane Database Syst Rev; 2022 Jan 07; 1(1):CD013453. PubMed ID: 34994987
    [Abstract] [Full Text] [Related]

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V.
    Cochrane Database Syst Rev; 2020 Dec 14; 12(12):CD013257. PubMed ID: 33316104
    [Abstract] [Full Text] [Related]

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V.
    Cochrane Database Syst Rev; 2021 Apr 30; 4(4):CD013257. PubMed ID: 33930176
    [Abstract] [Full Text] [Related]

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA.
    Cochrane Database Syst Rev; 2021 Mar 18; 3(3):CD010383. PubMed ID: 33734432
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y, Zhao Q, Liao Z, Ma Y, Ma D.
    Cancer; 2023 Apr 15; 129(8):1261-1275. PubMed ID: 36748799
    [Abstract] [Full Text] [Related]

  • 7. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
    Jiang J, Zhao C, Zhang F, Liu Z, Zhou K, Ren X, Wan Y.
    BMJ Open; 2022 Sep 19; 12(9):e060782. PubMed ID: 36123063
    [Abstract] [Full Text] [Related]

  • 8. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    Zhao M, Shao T, Shao H, Zhou C, Tang W.
    BMC Cancer; 2024 Feb 08; 24(1):186. PubMed ID: 38331773
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC, Liu YH, Ding KL, Liu YF, Zhao WJ, Zhu YJ, Chang XS, Chen YD, Xiao ZZ, Yu YY, Zhou R, Zhang HB.
    BMC Cancer; 2021 Nov 26; 21(1):1278. PubMed ID: 34836510
    [Abstract] [Full Text] [Related]

  • 10. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
    Zheng B, Jiang H, Yang W, Li Y, Liang B, Zhu J, Chen N, Chen M, Zhang M.
    Cancer Med; 2023 Aug 26; 12(15):15983-15997. PubMed ID: 37334877
    [Abstract] [Full Text] [Related]

  • 11. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
    Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xiang RL.
    Ann Palliat Med; 2020 Jul 26; 9(4):1782-1796. PubMed ID: 32527124
    [Abstract] [Full Text] [Related]

  • 12. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Elliott J, Bai Z, Hsieh SC, Kelly SE, Chen L, Skidmore B, Yousef S, Zheng C, Stewart DJ, Wells GA.
    PLoS One; 2020 Jul 26; 15(2):e0229179. PubMed ID: 32074131
    [Abstract] [Full Text] [Related]

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 14. Maintenance therapy for chronic lymphocytic leukaemia.
    Lee CH, Wu YY, Huang TC, Lin C, Zou YF, Cheng JC, Chen PH, Jhou HJ, Ho CL.
    Cochrane Database Syst Rev; 2024 Jan 04; 1(1):CD013474. PubMed ID: 38174814
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat.
    Ont Health Technol Assess Ser; 2010 Jan 04; 10(24):1-48. PubMed ID: 23074402
    [Abstract] [Full Text] [Related]

  • 18. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J, Beavers N, Nilsson FOL, Iadeluca L, Lowry C.
    Appl Health Econ Health Policy; 2023 Jul 04; 21(4):661-672. PubMed ID: 37173513
    [Abstract] [Full Text] [Related]

  • 19. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI.
    Future Oncol; 2021 May 04; 17(14):1709-1719. PubMed ID: 33569983
    [Abstract] [Full Text] [Related]

  • 20. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
    Wang Y, Shen S, Hu P, Geng D, Zheng R, Li X.
    Cancer Med; 2022 Dec 04; 11(23):4491-4500. PubMed ID: 35616090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.